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Both environmental exposure and genes affect 
childhood brain tumor (CBT) development. 
Ionizing radiation to the head and selected 
heritable syndromes are established risk factors 
(Fisher et al. 2007). However, these account 
for only a small proportion of CBT cases. 
Several epidemiologic studies suggest pesti-
cides might be associated with CBT (Infante-
Rivard and Weichenthal 2007), but most 
relied on retrospective questionnaire data with 
little detail. One study that considered the 
type and timing of pesticide exposure observed 
an increased risk of CBT with prenatal expo-
sure to flea/tick products, but not herbicides, 
fungicides, or molluscicides (Pogoda and 
Preston-Martin 1997). The specificity of this 
finding is interesting because the major classes 
of insecticides—organophosphorus (OP), car-
bamate, organochlorine (OC), and pyrethrin/
pyrethroid—readily cross the blood–brain 
barrier and target the nervous system, whereas 
pesticides aimed at plants and fungi inherently 
rely on different mechanisms of action.
Because constitutive genetic variation 
influences insecticide metabolism, we previ-
ously examined whether CBT is associated 
with two single nucleotide polymorphisms 
(SNPs) in the gene that codes for paraoxonase 
(PON1) (Searles Nielsen et al. 2005). We 
observed no association between CBT and 
the single coding region SNP PON1Q192R but 
a strong dose–response relationship between 
CBT and PON1C–108T, a promoter-region 
SNP associated with enzyme levels. CBT risk 
was increased among children who presumably 
had a reduced ability to detoxify chlorpyrifos 
and diazinon, the most common residential 
insecticides for many years, and this associa-
tion was restricted to children whose homes 
had been chemically treated for insects. Here 
we examine these SNPs and six additional 
genetic polymorphisms that affect insecticide 
metabolism using an expanded number of 
cases and controls born in Washington State 
and California.
Materials and Methods
Participant selection and specimen retrieval. 
This analysis includes children enrolled in 
the U.S. West Coast CBT Study, a popu-
lation-based case–control study described 
previously (Preston-Martin et al. 1996). 
Briefly, those cases were children diag-
nosed from 1984 through 1991 with a 
primary tumor of the brain, cranial nerves, 
or meninges [International Classification of 
Diseases–Oncology (ICD-O) (World Health 
Organization 1976) codes 191.0–192.1] and 
who were identified through the Surveillance, 
Epidemiology and End Results registries in the 
Seattle–Puget Sound region of Washington, 
the San Francisco–Oakland area of California, 
and Los Angeles County, California. Control 
children living in the same counties were iden-
tified by random digit dialing. Children with 
a biological mother who spoke English or 
Spanish in a home with a telephone were eli-
gible. After informed consent, interviews were 
completed with the mothers of 75% of con-
trols who met these criteria (88% screened) 
and who were invited to participate while 
being frequency matched to cases by age and 
sex (1:1 in Los Angeles and 2:1 elsewhere) and 
73% of cases for whom physician permission 
was received (97% of all cases) and who met 
the above criteria (or potentially met them but 
who were not located, 13% of all cases).
We identified those participating children 
for whom a dried blood spot (DBS) from 
newborn screening might still be archived at 
the Washington State Department of Health 
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Ba c k g r o u n d: Insecticides that target the nervous system may play a role in the development of 
childhood brain tumors (CBTs). Constitutive genetic variation affects metabolism of these chemicals.
Me t h o d s : We analyzed population-based case–control data to examine whether CBT is associated 
with the functional genetic polymorphisms PON1C–108T, PON1Q192R, PON1L55M, BCHEA539T, 
FMO1C–9536A, FMO3E158K, ALDH3A1S134A, and GSTT1 (null). DNA was obtained from new-
born screening archives for 201 cases and 285 controls, ≤ 10 years of age, and born in California or 
Washington State between 1978 and 1990. Conception-to-diagnosis home insecticide treatment 
history was ascertained by interview.
re s u l t s: We observed no biologically plausible main effects for any of the metabolic polymor-
phisms with CBT risk. However, we observed strong interactions between genotype and insecticide 
exposure during childhood. Among exposed children, CBT risk increased per PON1–108T allele 
[odds ratio (OR) = 1.8; 95% confidence interval (CI), 1.1–3.0] and FMO1–9536A (*6) allele (OR = 
2.7; 95% CI, 1.2–5.9), whereas among children never exposed, CBT risk was not increased (PON1: 
OR = 0.7; 95% CI, 0.5–1.0, interaction p = 0.005; FMO1: OR = 1.0; 95% CI, 0.6–1.6, interac-
tion p = 0.009). We observed a similar but statistically nonsignificant interaction between child-
hood exposure and BCHEA539T (interaction p = 0.08). These interactions were present among both 
Hispanic and non-Hispanic white children.
co n c l u s i o n: Based on known effects of these variants, these results suggest that exposure in child-
hood to organophosphorus and perhaps to carbamate insecticides in combination with a reduced 
ability to detoxify them may be associated with CBT. Confirmation in other studies is required.
key w o r d s : acetylcholinesterase inhibition, childhood cancer, children, gene–environment inter-
action, insecticides, pesticides, xenobiotic metabolism. Environ Health Perspect 118:144–149 
(2010).  doi:10.1289/ehp.0901226 available via http://dx.doi.org/ [Online 5 October 2009]Child brain tumors and insecticide metabolism
Environmental Health Perspectives  •  v o l u m e  118 | n u m b e r 1 | January 2010  145
(born in Washington in 1978–1990) or the 
California Department of Public Health (born 
in California in 1982–1990). As detailed 
elsewhere (Searles Nielsen et al. 2008), DBS 
were located and anonymized for 88% of 
children for whom a specimen was sought in 
Washington, including 66 (94%) cases and 
137 (86%) controls included in both the pres-
ent and earlier (Searles Nielsen et al. 2005) 
CBT–PON1 analyses. Similar specimen col-
lection methods were used in California, 
where DBS for 86% of sought children were 
located, including 26 (93%) cases and 50 
(75%) controls from San Francisco and 110 
(92%) cases and 99 (85%) controls from Los 
Angeles. Institutional review board approv-
als from all relevant agencies were obtained 
before the study began.
Genotyping. The Functional Genomics 
Core Laboratory of the Center for Ecogenetics 
and Environmental Health at the University 
of Washington in Seattle, which was unaware 
of case status, obtained DNA using com-
mercially available kits [QIAamp DNA Mini 
Kit for Washington DBS (Searles Nielsen 
et al. 2005) and the Repli-g Kit (Paynter et al. 
2006) for California DBS; Qiagen, Valencia, 
CA], determined glutathione S-transferase 
theta 1 (GSTT1) null status (Kelada et al. 
2003), and used custom TaqMan Detection 
System–based assays-by-Design service 
(Applied Biosystems, Inc., Foster City, CA) 
for seven functional pesticide metabolism 
SNPs (Table 1) and PON2S311C (rs7493). We 
included PON2S311C to investigate whether 
CBT–PON1 associations might be a result 
of PON1’s generic antioxidant capabilities, 
because PON2 does not metabolize OPs 
(Draganov et al. 2005). Fragment lengths 
required for the TaqMan assays ranged from 
84 to 202 bp (base pairs) and from 215 to 
480 bp for the GSTT1 assay. Negative con-
trols (no DNA) and sequencing-verified posi-
tive controls were included in each batch of 
analyses. Results were verified by sequenc-
ing as needed, and approximately 10% of all 
samples were reassayed. For the Washington 
samples, blind duplicate or quadruplicate 
specimens for 6% of cases and 6% of con-
trols were assayed for all nine polymorphisms 
[205 of 207 (99.0%) pairs agreed], and the 
PON1C–108T assay results were confirmed 
using a different TaqMan assay (100% con-
cordance). Complete genotyping data were 
available for all but two cases and one control.
Insecticide exposure assessment. During 
a structured in-person interview, children’s 
mothers reported whether they or anyone else 
had chemically treated the child’s home for 
pests listed on a show card that included ter-
mites, fleas, ants, cockroaches, silverfish, or 
“other” pests. The questionnaire inquired 
separately about treatments during pregnancy 
(1 month before conception until birth) and 
childhood (birth until diagnosis for cases or 
comparable reference date for controls). We 
considered these distinct periods of exposure 
separately in our analyses because a) the dose 
of the active ingredients and their interme-
diates (e.g., oxons) may be altered by mater-
nal enzymes when the child is in utero; b) the 
child’s enzyme levels [those shown in Table 1 
and oxon-forming cytochrome P450 (CYP) 
isoforms] vary developmentally—some in 
direct response to birth; and c) timing of insec-
ticide exposure appears important for CBT 
(Pogoda and Preston-Martin 1997). These data 
were available for all but one case and one con-
trol with DBS and were ascertained an average 
of 5.3 and 6.4 years, respectively, after birth.
Supplementary data collected in a fol-
low-up study in Los Angeles (Pogoda and 
Preston-Martin 1997) allowed us also to con-
sider exposure to any residential insecticides 
(treatment of the home, yard, garden, pets, 
and/or for lice) and exposure to the most 
common specific treatments (for fleas/ticks, 
for nuisance insects) among 80 (40%) cases 
and 68 (24%) controls in the present work 
(73% of cases and 69% of controls from Los 
Angeles and with DBS).
Statistical analysis. We used uncondi-
tional logistic regression to compute odds 
Table 1. Functional effect and hypothesized “high-risk” alleles in genetic pesticide metabolism polymorphisms.
Enzyme Function Expression Polymorphism Hypothesized “high-risk” allele
Paraoxonase (PON1) Hydrolyzes environmentally and CYP- 
activated intermediates (AChE-inhibiting 
oxons) of selected OP insecticides (e.g., 
chlorpyrifos, diazinon, parathion) such 
that they cannot inhibit AChE
In blood and liver; expressed during 
the fetal period; increases with 
gestational age and after birth; 
adult levels reached at 6–25 
months of age
PON1C–108T (rs705379), 
adjacent to Sp1 binding 
site in the promoter 
region
T: Reduced PON1 levels in neonates (63% 
lower in those with 2 vs. 0 variants) (Chen 
et al. 2003) and adults (Brophy et al. 
2001; Leviev and James 2000)
PON1Q192R (rs662), amino 
acid substitution near 
the catalytic center
Q: Reduced brain protection in mice (Li 
et al. 2000), metabolism in human liver 
microsomes (Mutch et al. 2007), and 
metabolism in vitro (Davies et al. 1996) 
for chlorpyrifos but not diazinon
PON1L55M (rs854560), 
amino acid substitution
M: Less stable PON1 (Leviev et al. 2001)
Butyrylcholinesterase 
(BuChE)
Sequesters all OP and carbamate 
insecticides through stoichiometric (1:1) 
binding such that they cannot inhibit 
AChE
In brain, blood, lung, intestine, and 
embryonic tissues
BCHEA539T (rs1803274), 
amino acid substitution
T (“K variant”): 30–40% reduction in BuChE 
activity (Babaoglu et al. 2004; Bartels 
et al. 1992; Maetzler et al. 2009)
Flavin-containing 
monooxygenase 
(FMO1 and FMO3)
Metabolize some OP insecticides (e.g., 
phorate, terbufos, fenthion, disulfoton, 
fonofos) and some carbamate 
insecticides (e.g., aldicarb and 
methiocarb); oxidizes the thioether sulfur 
to form a sulfoxide; does not form oxons
FMO1: highest in the embryo during 
extensive brain development, and 
high throughout the fetal period; 
decreases in the liver and brain 
after birth; also present in the 
small intestine and lung (at levels 
greater than liver after birth)
FMO1C–9536A 
(rs12720462), in a 
promoter region YY1 
binding site
A (*6): Eliminates YY1 binding, 2- to 3-fold 
loss of promoter activity (Hines et al. 
2003)
Metabolize ethylene thiourea, metabolite 
of ethylene bisdithiocarbamate 
fungicides (e.g., maneb, mancozeb, 
zineb, metiram)
FMO3: Not present in the 
postembryonic fetal period; in brain 
by 1–2 years of age
FMO3E158K (rs2266782), 
amino acid substitution
K: One-third activity (Lattard et al. 2003)
Aldehyde 
dehydrogenase 3A1 
(ALDH3A1)
Metabolizes a product of permethrin 
(pyrethroid insecticide)
In brain, stomach, and lung ALDH3A1S134A 
(rs887241), amino acid 
substitution
A: May reduce enzyme activity (Satomichi 
et al. 2000) 
Glutathione 
S-transferase theta 1 
(GSTT1)
Metabolizes OC insecticides (DDT, lindane), 
OP insecticides (methylparathion, EPN), 
triazine herbicides (atrazine), and 
chloroacetanilide herbicides (alochlor)
In brain, liver (including during the 
fetal period), lung, small intestine, 
and blood (erythrocytes)
GSTT1 null *0 (null): No GSTT1 enzyme
Abbreviations: DDT, dichlorodiphenyltrichloroethane; EPN, ethyl p-nitrophenyl phenylphosphonothioate.Searles Nielsen et al.
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ratios (OR) and 95% confidence intervals 
(CIs) of CBT in relation to each polymor-
phism. The GSTT1 assay provided dichoto-
mous (any/no GSTT1) results. For all other 
polymorphisms we checked Hardy–Weinberg 
equilibrium by exact chi-square test [butyryl-
cholinesterase (BCHE) and flavin-contain-
ing monooxygenase 1 (FMO1) SNPs, with a 
minor allele frequency of ≤ 0.20] or Pearson’s 
chi-square test (other SNPs) and, unless 
noted, modeled genotype linearly (coded 
the variable as 0, 1, or 2 hypothesized “high-
risk” alleles) (Table 1). Likelihood ratio tests 
confirmed that single linear variables were 
appropriate. We adjusted all models for study 
center, sex, diagnosis/reference age, and race/
ethnicity [African American (either parent 
African American), Hispanic (not African 
American, and either parent Hispanic), white 
(both parents non-Hispanic white), Asian/
other]. We excluded five cases and two con-
trols with unknown race/ethnicity.
We conducted haplotype analyses for the 
four PON SNPs and the two FMO SNPs. 
We inferred haplotypes (PHASE software, 
version 2.1; Stephens and Donnelly 2003) 
while accounting for distance between SNPs, 
and using 100 additional control DBS (anon-
ymous children born in Washington in 1980–
1991). We modeled haplotype linearly while 
including children for whom both alleles were 
sufficiently frequent (> 1%) and estimated 
with > 80% probability.
To examine the potential for gene– 
insecticide interaction, we estimated separate 
CBT-genotype ORs for a) unexposed children 
(never exposed during pregnancy or child-
hood), b) children exposed during pregnancy, 
and c) children exposed during childhood. 
We formally assessed interaction on a multi-
plicative scale in logistic regression; reported 
p-values are from a single product term (geno-
type multiplied by dichotomous exposure). 
Prenatal and childhood insecticide exposure 
were correlated, so, when possible, we strati-
fied prenatal exposure models by childhood 
exposure, and vice versa. We attempted to 
confirm all observed interactions in case-
only gene–environment models (Khoury and 
Flanders 1996), because these would not be 
influenced by the composition of our control 
group or their reporting of insecticide use.
We checked whether our main gene and 
gene–insecticide CBT ORs were consistent 
across racial/ethnic groups, age, and study 
center. For these comparisons we dichoto-
mized diagnosis/reference age at the median 
(3 years), combined centers (California, 
Washington), and examined stratum-specific 
estimates for sufficiently large racial/ethnic 
groups (Hispanic, non-Hispanic white). 
We also considered CBT histologic sub-
type. Included among the present sample 
were ICD-O histology codes 9380, 9382, 
9400, 9401, 9420, 9421 (astroglial tumors, 
n = 96, 48% cases), 9470, 9471, 9473 
(medulloblastoma/primitive neuroectodermal 
tumors, n = 55, 27% cases), and 9391–9393 
(ependymoma, n = 25, 12% cases).
Results
All children were ≤ 10 years of age at   diagnosis/
reference, and most were < 5 years of age 
(Table 2). Proportionally more cases than con-
trols were Hispanic or nonwhite. Only three 
cases and three controls had a heritable syn-
drome that predisposes to brain tumor, or 
a first-degree relative with a history of brain 
tumor. Farm residence and maternal prenatal 
agricultural occupation also were uncommon 
(2–4% cases, 1–2% controls).
Residential insecticide exposure. During 
pregnancy, proportionally more mothers of 
cases (27%) than controls (21%) reported 
treatment of the home for termites, fleas, 
ants, cockroaches, silverfish, or other pests 
(Table 2); we did not observe this difference 
in Washington State, where treatment was 
less prevalent than in California (data not 
shown). In contrast, treatment of the home 
for insects during childhood was more com-
mon among controls (33%) than among cases 
(23%) (Table 2), a difference observed in 
all study centers (data not shown). Among 
children in the pesticide follow-up study in 
Los Angeles, any residential insecticide use 
was prevalent both during pregnancy and 
childhood (≥ 70% of cases and controls). In 
general, use of flea/tick products was more 
common among cases than among controls, 
and the reverse for nuisance pests.
CBT and pesticide metabolism poly-
morphisms. Genotype frequencies were in 
Hardy–Weinberg equilibrium for each racial/
ethnic group (all p-values > 0.05). Overall, 
we observed no marked differences between 
cases and controls for any polymorphism 
[see Supplemental Material, Table 1 (avail-
able online at doi:10.1289/ehp.0901226.S1 
via http://dx.doi.org)]. Any potential hetero-
geneity in the CBT–genotype ORs by race/
ethnicity was not statistically significant (all 
interaction p-values > 0.24). Main effect ORs 
for all racial/ethnic groups combined (and 
Table 2. Characteristics of children with and without brain tumors, West Coast Childhood Brain Tumor 
Study, children with genotyping data and born in California or Washington State in 1978–1990 [no. (%)].a
Characteristic Cases (n = 201) Controls (n = 285)
Study center
Los Angeles 110 (55) 99 (35)
San Francisco 25 (12) 50 (18)
Seattle 66 (33) 136 (48)
Birth year
1978–1984 99 (49) 141 (49)
1985–1990 102 (51) 144 (51)
Age (years)
< 5 167 (83) 222 (78)
5–10 34 (17) 63 (22)
Child’s race/ethnicityb
White 105 (54) 192 (68)
Hispanic 62 (32) 61 (22)
African American 14 (7) 13 (5)
Asian/other 15 (8) 17 (6)
Male 121 (60) 168 (59)
Brain tumor in first-degree relative, or personal/
family history of Li-Fraumeni syndrome, 
neurofibromatosis, or tuberous sclerosis
3 (1) 3 (1)
Farm residence during pregnancy/childhood 9 (4) 5 (2)
Maternal agricultural occupation in pregnancy 4 (2) 4 (1)
Chemical treatment of home for insect pestsc
During pregnancyd 55 (27) 60 (21)
During childhood, up to diagnosis/referencee 46 (23) 94 (33)
Insecticides for home, yard, garden, pets, or licef
During pregnancyd 61 (78) 48 (77)
Fleas or ticks 33 (41) 19 (28)
Nuisance pestsg 43 (57) 39 (60)
During childhoode 60 (77) 46 (70)
Fleas or ticks 33 (41) 22 (32)
Nuisance pestsg 41 (51) 40 (59)
aAll study participants for whom a usable DBS was obtained from newborn screening archives in California or 
Washington State. bAfrican American: either parent African American; Hispanic: either parent Hispanic and neither par-
ent African American; white: both parents non-Hispanic white; percentages exclude five cases and two controls with 
non-Hispanic white mothers and for whom paternal race was unknown. cTermites, fleas, ants, cockroaches, silverfish, 
or other pests; percentages exclude participants for whom prenatal (one control) or childhood (one case, one control) 
insecticide exposure was unknown. dFrom 1 month before conception until birth. eBetween birth and diagnosis (cases) 
or comparable reference date (controls). fBased on children also participating in a pesticide follow-up study in Los 
Angeles only (Pogoda and Preston-Martin 1997) and with respective exposure data (76–80 cases and 65–68 controls). 
gAnts, cockroaches, and other nuisance pests; does not include termites or fleas.Child brain tumors and insecticide metabolism
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adjusted for this factor) were close to null, 
with the possible exception of BCHEA539T and 
FMO3E158K (Table 3). FMO haplotype analy-
ses suggested that any increased CBT risk in 
relation to the FMO3158K allele was restricted 
to children with two FMO1–9536C alleles, but 
95% CIs were wide (data not shown).
Genotype–insecticide interactions. We 
observed statistically significant interactions 
between insecticide treatment of the home dur-
ing childhood and two promoter region pesti-
cide metabolism SNPs (interaction p = 0.005 
for PON1C–108T, 0.009 for FMO1C–9536A; 
Table 3). We also observed an interac-
tion for the coding region SNP BCHEA539T 
of borderline statistical significance (interac-
tion p = 0.08). ORs per “high-risk” (hypoth-
esized poor detoxification) allele (PON1–108T, 
FMO1–9536A, and BCHE539T) were greater 
among children whose homes had been treated 
during childhood than among children whose 
homes never had been treated. These interac-
tions were present among non-Hispanic white 
children (interaction p = 0.11 for PON1C–108T, 
0.04 for FMO1C–9536A, 0.04 for BCHEA539T) 
and Hispanic children (interaction p = 0.13 
for PON1C–108T, 0.12 for FMO1C–9536A, 0.16 
for BCHEA539T; Table 4). We observed the 
interactions between childhood insecticide 
exposure and PON1C–108T and FMO1C–9536A 
with or without exposure during pregnancy [all 
interaction p = 0.01–0.06; see Supplemental 
Material, Table 2 (doi:10.1289/ehp.0901226.
S1)]. These interactions also appeared inde-
pendent of nearby SNPs, because we observed 
the insecticide–FMO1C–9536A inter  action 
across FMO3E158K genotypes, and the insec-
ticide–PON1C–108T interaction when mod-
eling PON1–PON2 as a haplotype. The 
PON1C–108T interaction appeared to vary by 
age at diagnosis/reference: Among children 
< 3 years of age at diagnosis/reference, the OR 
per PON1–108T allele was 2.4 (95% CI, 1.0–
5.7) if exposed to insecticides and 0.5 (95% 
CI, 0.3–0.7) if unexposed (interaction p = 
0.001), and among older children 1.4 (95% 
CI, 0.7–2.7) if exposed and 1.2 (95% CI, 0.7–
2.0) if unexposed (interaction p = 0.69; data 
not shown). This did not appear to be a result 
of the correlation between age and birth year or 
between prenatal and childhood exposure.
When we stratified genotype ORs by home 
insecticide treatment during pregnancy, we 
observed variability between exposed and unex-
posed children for some of the pesticide metab-
olism polymorphisms (Table 3). For example, 
the GSTT1 null genotype was associated with 
a reduced risk of CBT only among the exposed 
children, and the “high-risk” FMO3158K allele 
was associated with an increased risk of CBT 
only among the unexposed children. However, 
none of the possible interactions between 
genotype and prenatal insecticide exposure 
was statistically significant (each interaction 
p > 0.15). Statistically significant or borderline 
interactions were suggested only in modestly 
sized subgroups involving PON1C–108T and 
FMO1C–9536A (data not shown).
Among children from Los Angeles with 
supplementary pesticide data, we observed 
possible interactions between both prena-
tal and childhood insecticide exposure and 
BCHEA539T (genotype dichotomized; interac-
tion p = 0.05–0.06 for any residential insec-
ticides, 0.05–0.13 for flea/tick products, 
and 0.06–0.16 for products for nuisance 
pests such as ants and cockroaches; data not 
shown). The “high-risk” BCHE539T allele 
was associated with increased CBT risk only 
among insecticide-exposed individuals.
Even within the larger sample, our abil-
ity to consider histologic tumor type was 
quite limited. Nonetheless, the interactions 
between insecticide treatment of the home 
during childhood and each of the three 
SNPs (PON1C–108T, FMO1C–9536A, and 
BCHEA539T) remained when we focused 
on our largest subgroup, astroglial tumors. 
However, these interactions were not strictly 
specific to this tumor type.
We were unable to formally confirm any 
interactions using case-only models because, 
among controls, genotype and exposure were 
not independent. Otherwise, these models 
supported all reported interactions.
Discussion
We attempted to build on prior studies of 
CBT and pesticide exposure by considering 
individual differences in the metabolism of 
insecticides that target the nervous system. We 
a priori designated a “high-risk” allele for each 
Table 3. Risk of CBT and functional pesticide metabolism polymorphisms and PON2, overall and by home 
insecticide treatment, West Coast Childhood Brain Tumor Study [OR (95% CI)].
Chemical treatment of the home for insect pestsa
Pesticide metabolism 
polymorphism 
All children Never 
(116 ca/162 co)b,d
Ever in pregnancy 
(53 ca/60 co)b,e
Ever in childhood 
(46 ca/94 co)b,f (196 ca/283 co)b,c
PON1C–108T 0.9 (0.7–1.2) 0.7 (0.5–1.0) 1.2 (0.7–2.0) 1.8 (1.1–3.0)*
PON1Q192R 1.0 (0.7–1.3) 1.0 (0.7–1.4) 0.8 (0.5–1.4) 0.9 (0.5–1.6)
PON1L55M 1.0 (0.8–1.3) 1.1 (0.8–1.6) 0.7 (0.4–1.3) 1.0 (0.6–1.7)
PON2S311C 0.9 (0.7–1.2) 0.9 (0.6–1.3) 0.6 (0.3–1.3) 1.1 (0.6–1.9)
BCHEA539T 0.7 (0.5–1.0)* 0.6 (0.4–1.0)* 0.9 (0.4–1.9) 1.3 (0.6–2.8)
FMO1C–9536A 1.1 (0.7–1.6) 1.0 (0.6–1.6) 0.9 (0.4–2.0) 2.7 (1.2–5.9)*
FMO3E158K 1.2 (0.9–1.7) 1.4 (1.0–2.0) 1.0 (0.5–1.8) 1.1 (0.7–2.0)
ALDH3A1S134A 1.1 (0.8–1.4) 1.1 (0.8–1.6) 1.6 (0.9–2.8) 1.0 (0.6–1.7)
GSTT1 (null) 0.8 (0.5–1.3) 1.0 (0.5–2.0) 0.3 (0.1–1.0) 0.4 (0.1–1.3)
Abbreviations: ca, cases; co, control.
aBased on maternal report of chemical treatment of the home for termites, fleas, ants, cockroaches, silverfish, or 
“other” pests by a professional, the mother, or someone else. bOR and 95% CI, for GSTT1 null versus non-null or for 
all other polymorphisms per “high-risk” allele [PON1–108T, PON1192Q, PON155M, BCHE539T, FMO1–9536A (*6), FMO3158K, 
ALDH3A1134A; see Table 1], or PON2311C, adjusted for race/ethnicity (African American, Hispanic, non-Hispanic white, 
Asian/other), study center, sex, and age at diagnosis/reference (continuous). cExcludes five cases and two controls with 
unknown race/ethnicity. dNo chemical treatment of the home for insect pests any time between 1 month before concep-
tion and diagnosis/reference; excludes three cases and two controls with unknown race/ethnicity. eChemical treatment 
of the home for insect pests any time from 1 month before conception and birth; excludes two cases with unknown race/
ethnicity. fChemical treatment of the home for insect pests any time between birth and diagnosis/reference; excludes 
two cases with unknown race/ethnicity. *p < 0.05.
Table 4. Risk of CBT and PON1C–108T, FMO1C–9536A, and BCHEA539T, by home insecticide treatment during 
childhood and child’s race/ethnicity,a West Coast Childhood Brain Tumor Study [OR (95% CI)].b
Chemical treatment of the home  
during childhood for insect pestsc
Pesticide metabolism polymorphism Yes No
PON1C–108T (per T allele)
Non-Hispanic white (105 ca/191 co)d 1.5 (0.8–2.8) 0.8 (0.6–1.3)
Hispanic (62 ca/61 co)e 1.6 (0.5–5.7) 0.6 (0.3–1.0)
FMO1C–9536A (AA/AC vs. CC)
Non-Hispanic white (105 ca/191 co)d 3.0 (1.1–8.3) 0.7 (0.3–1.7)
Hispanic (62 ca/61 co)e 3.3 (0.5–23.8) 0.6 (0.3–1.3)
BCHEA539T (TT/AT vs. AA)
Non-Hispanic white (105 ca/191 co)d 1.2 (0.5–3.1) 0.5 (0.3–1.0)
Hispanic (62 ca/61 co)e 2.9 (0.2–34.3) 0.5 (0.2–1.2)
Abbreviations: ca, cases; co, control.
aHispanic: neither parent African American and one or both parents Hispanic; non-Hispanic white: both parents non-
Hispanic white. bData are OR (95% CI) obtained from a single model for each racial/ethnic group containing variables for 
genotype, childhood exposure (any vs. none), gene–exposure product term, study center, sex, and age at diagnosis/ref-
erence (continuous). cBased on maternal report, chemical treatment of the home for termites, fleas, ants, cockroaches, 
silverfish or “other” pests by a professional, the mother, or someone else, between birth and diagnosis/reference. 
dData are for 28 cases/73 controls exposed during childhood and 77 cases/118 controls unexposed during childhood 
(including 9 cases/11 controls with prenatal exposure); excludes one control without exposure information. eData are 
for 12 cases/12 controls exposed during childhood and 50 cases/49 controls unexposed during childhood (including 14 
cases/17 controls with prenatal exposure).Searles Nielsen et al.
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polymorphism based on the expected func-
tional impact with respect to acetylcholinest-
erase (AChE) inhibition (OP and carbamate 
insecticides; PON1, BCHE, FMO1, FMO3, 
and GSTT1 polymorphisms) and ion channel 
stimulation [OC and pyrethroid insecticides; 
aldehyde dehydrogenase 3A1 (ALDH3A1) 
and GSTT1 polymorphisms]. Although some 
insecticides metabolized by these enzymes 
are ubiquitous in the environment or diet, 
ORs for CBT in relation to the hypothesized 
“high-risk” allele for the nine polymorphisms 
were close to the null, or fluctuated equally 
above and below the null. However, we 
observed interactions between genotype and 
chemical treatment of the home for insects 
during childhood for three functional SNPs 
located on different chromosomes: PON1C–
108T, FMO1C–9536A, and BCHEA539T. The 
direction of these interactions was consistent 
and biologically plausible. Moreover, they 
were present in each of our two largest racial/
ethnic groups.
PON1–108T and BCHE539T variants are 
respectively associated with reduced in vivo 
activity of PON1 (Brophy et al. 2001; Chen 
et al. 2003; Leviev and James 2000) and the 
butyrylcholinesterase enzyme (BuChE) 
(Babaoglu et al. 2004; Bartels et al. 1992; 
Maetzler et al. 2009). Both neutralize AChE 
inhibitors: PON1 hydrolyzes selected OPs, 
notably chlorpyrifos and diazinon (Furlong 
2007), and BuChE sequesters all OP and car-
bamate insecticides (Cokuğraş 2003). In vitro 
studies suggest that FMO1–9536A materially 
reduces promoter activity (Hines et al. 2003). 
Its product, flavin-containing monooxygenase 1 
(FMO1), oxidizes the thioether sulfur of some 
OP and carbamate insecticides (Hajjar and 
Hodgson 1980), and for some substrates (e.g., 
fenthion; Furnes and Schlenk 2004) the result-
ing sulfoxide is a weaker AChE inhibitor than is 
its parent compound. FMO1 does not appear 
to oxidize other sulfur atoms in OP insecticides 
(Hajjar and Hodgson 1980) (activate the parent 
compound to its oxon). Thus, our results are 
consistent with the possibility that children with 
a reduced ability to metabolize OP and perhaps 
carbamate insecticides might be at increased risk 
of CBT when sufficiently exposed. The appar-
ent specificity of the results to AChE inhibitors 
is interesting but in part reflects our selection of 
polymorphisms. Also, even if our results suggest 
a biological impact of the SNPs and insecti-
cides, it is unknown whether this is a result of 
AChE inhibition per se or to some other effect 
of AChE-inhibiting insecticides used residen-
tially during the study period. For example, 
chlorpyrifos and diazinon induce neurotoxic 
effects in neonatal rats, even when administered 
at levels insufficient to inhibit AChE (Slotkin 
et al. 2008).
The consistency of results across the three 
SNPs for which we observed an interaction 
with childhood insecticide exposure is com-
pelling but nevertheless could represent 
chance associations. Our results were based 
on modest numbers, and these SNPs have not 
been studied in independent samples of brain 
tumor patients, making the probability of 
false positives high (Wacholder et al. 2004). 
The interaction involving FMO1C–9536A 
must be interpreted especially cautiously. 
Whether the net effect of FMO1 would be 
protective may depend on the insecticide 
(Buronfosse et al. 1995; Furnes and Schlenk 
2004; Levi and Hodgson 1988). Although 
children are exposed to FMO1 insecticide 
substrates, including disulfoton used resi-
dentially outdoors, we have not identified an 
FMO1-metabolized insecticide registered for 
residential use indoors. The interaction with 
home insecticide exposure in childhood is 
also puzzling because FMO1 enzyme levels 
in the brain and liver drop substantially after 
birth (Koukouritaki et al. 2002; Zhang and 
Cashman 2006). Still, FMO1 is not absent 
from these sites and is expressed at greater 
levels in the lung and small intestine (Zhang 
and Cashman 2006), presumably relevant 
to inhaled and hand-to-mouth exposure, 
  respectively.
The presence of interactions between 
genotype and insecticide exposure occurring 
during childhood, but generally not during 
pregnancy, deserves further comment. During 
prenatal development, maternal enzymes serve 
as a first line of defense against exogenous 
exposures, and without maternal biospecimens 
we were unable to directly examine the effect 
of this. Also, perhaps fetal expression of some 
enzymes is too low, regardless of genotype, to 
alter insecticide dose sufficiently to protect 
the brain; here again, maternal enzymes may 
be important. Our data do not suggest a lack 
of effect of insecticide exposure during this 
potentially sensitive period, but rather a lack 
of synergism with fetal genotype.
We did not observe interactions for other 
PON or FMO SNPs. None were in the pro-
moter region of their respective genes. Also, 
the effect of the PON1Q192R amino acid 
change is dependent on the substrate, and 
the R isoform may be protective for chlor-
pyrifos but not diazinon (Davies et al. 1996; 
Li et al. 2000; Mutch et al. 2007). FMO1 
metabolizes insecticides better than FMO3 
(Furnes and Schlenk 2005; Leoni et al. 2008; 
Usmani et al. 2004). Perhaps more important, 
given our results for FMO3E158K, this coding 
region SNP is in linkage disequilibrium with 
promoter region polymorphisms that confer 
opposing effects on FMO3 enzyme activity 
(Phillips and Shephard 2008).
The childhood insecticide–PON1C–108T 
interaction was confined to children < 3 years 
of age. This polymorphism has a greater effect 
on PON1 levels in neonates than in adults 
(Chen et al. 2003), and adult levels are reached 
before 3 years of age (Cole et al. 2003). In 
addition, by this age diet is the main source 
of chlorpyrifos (Buck et al. 2001; Clayton 
et al. 2003), so in older children dietary 
exposure to chlorpyrifos and diazinon may 
have overwhelmed any interaction between 
PON1C–108T and residential exposure.
Since the time when the children in our 
study may have been exposed to home insec-
ticides, chlorpyrifos and diazinon have been 
phased out of residential use in the United 
States. Nonetheless, children remain exposed 
to these and other AChE inhibitors not only 
via the diet but also potentially via drift from 
use in agricultural areas, on golf courses, and 
for mosquito control. In the home, OP and 
carbamate insecticides remain, for example, 
in topical treatments for lice (malathion) 
and flea collars (tetrachlorvinphos, carbaryl, 
propoxur). Therefore, the present study may 
have had an increased ability to observe the 
reported interactions because of the greater 
residential use of AChE inhibitors, yet our 
results remain relevant.
Another strength of our study is the use 
of archived DBS, available for participants 
regardless of survival status. This makes it 
unlikely that a relationship between geno-
type and responsiveness to treatment could 
underlie the observed interactions. Other 
opportunities for selection bias were present, 
including during specimen collection (Searles 
Nielsen et al. 2008). Although it is there-
fore difficult to rule out bias in main effects, 
gene–environment interactions are generally 
unaffected by selection bias (Morimoto et al. 
2003). Further, despite the potential for dif-
ferential reporting of past exposures, this more 
likely attenuated than caused the interactions 
we report (Garcia-Closas et al. 1999).
To date, this is the largest study of CBT 
and genetic polymorphisms. Studies with more 
participants are needed to clarify the reported 
associations. Inclusion of additional polymor-
phisms in FMO3 and BCHE, especially those 
in the promoter region, would be worthwhile. 
These have been less studied than coding region 
polymorphisms in relation to cancer, but they 
appeared to be critical here. Objective measure-
ment of specific insecticides in environmental 
or biological specimens, and detailed interview 
data on the timing of exposure (e.g., during 
spermatogenesis, by pregnancy trimester, and 
by childhood age) also would be important. 
Although our results most strongly indicated 
the importance of exposures during early child-
hood, it is likely that other periods are also 
important, notably prenatal development. In 
studies that do consider exposures before birth, 
it would be useful to assess parents’ genotypes 
and levels of selected enzymes, including 
PON1 and FMO1 that are relatively stable 
over time in adults.Child brain tumors and insecticide metabolism
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